<li>alfentanil<p>lidocaine increases toxicity of alfentanil by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>belladonna and opium<p>lidocaine increases toxicity of belladonna and opium by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>buprenorphine<p>lidocaine increases toxicity of buprenorphine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>buprenorphine buccal<p>lidocaine increases toxicity of buprenorphine buccal by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>butorphanol<p>lidocaine increases toxicity of butorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>codeine<p>lidocaine increases toxicity of codeine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>dextromoramide<p>lidocaine increases toxicity of dextromoramide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>diamorphine<p>lidocaine increases toxicity of diamorphine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>difenoxin hcl<p>lidocaine increases toxicity of difenoxin hcl by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>diphenoxylate hcl<p>lidocaine increases toxicity of diphenoxylate hcl by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>dipipanone<p>lidocaine increases toxicity of dipipanone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>hydrocodone<p>lidocaine increases toxicity of hydrocodone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>hydromorphone<p>lidocaine increases toxicity of hydromorphone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>levorphanol<p>lidocaine increases toxicity of levorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>lily of the valley<p>lidocaine, lily of the valley.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>meperidine<p>lidocaine increases toxicity of meperidine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>methadone<p>lidocaine increases toxicity of methadone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>morphine<p>lidocaine increases toxicity of morphine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>nalbuphine<p>lidocaine increases toxicity of nalbuphine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>omeprazole<p>omeprazole will decrease the level or effect of lidocaine by  affecting hepatic enzyme CYP1A2 metabolism. Minor/Significance Unknown.</p></li><li>opium tincture<p>lidocaine increases toxicity of opium tincture by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>oxycodone<p>lidocaine increases toxicity of oxycodone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>oxymorphone<p>lidocaine increases toxicity of oxymorphone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>papaveretum<p>lidocaine increases toxicity of papaveretum by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>pentazocine<p>lidocaine increases toxicity of pentazocine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>sufentanil<p>lidocaine increases toxicity of sufentanil by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>tapentadol<p>lidocaine increases toxicity of tapentadol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li><li>tramadol<p>lidocaine increases toxicity of tramadol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of increased CNS depression.</p></li>